title: Long-term results of the use of oxybutynin for the treatment of plantar hyperhidrosis.
abstract: BACKGROUND
  Plantar hyperhidrosis is a common illness with significant impact on quality of life. Oxybutynin presents good short-term results, but longer follow-up results are lacking. We evaluated oxybutynin effectiveness in patients who were not surgically treated and who had at least six months of follow-up.
  
  
  METHODS
  From September 2007 to September 2013, 85 consecutive patients were enrolled in our institutional protocol for the "pharmacological-first" treatment of primary plantar hyperhidrosis with oxybutynin. Eight patients were lost to follow-up, 15 patients have not yet been under treatment for six months, and data were available for 39 patients (all female) treated for at least six months. Data at the start of the protocol, six weeks after beginning treatment, and at their final visit were analyzed.
  
  
  RESULTS
  Twenty-three of the 77 patients (29.87%) did not improve after pharmacological therapy. From the 39 patients with more than six months of follow-up (median 16.9 months, range 9-71), 79.5% reported moderate/great improvement in excessive plantar sweating after six weeks of treatment, and this rate increased to 84.7% in the last follow-up visit; 82.85% showed improvement in other sites presenting hyperhidrosis. Dry mouth was the most common side effect; 51.6% of patients reported it to be moderate/severe at the last visit.
  
  
  CONCLUSIONS
  In patients with good initial response to oxybutynin, more than 82% presented moderate or great improvement in plantar and other sites' excessive sweating; dry mouth was the most common side effect but was tolerable and did not lead any patient to interrupt treatment.
authors.affiliation: Department of Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Division of Vascular Surgery, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Nelson
authors.initials: N
authors.lastname: Wolosker
authors.forename: Marcelo P
authors.initials: MP
authors.lastname: Teivelis
authors.forename: Mariana
authors.initials: M
authors.lastname: Krutman
authors.forename: Rafael P
authors.initials: RP
authors.lastname: de Paula
authors.forename: Paulo
authors.initials: P
authors.lastname: Kauffman
authors.forename: José R M
authors.initials: JR
authors.lastname: de Campos
authors.forename: Pedro
authors.initials: P
authors.lastname: Puech-Leão
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D002648:Child; D005260:Female; D005533:Foot Dermatoses / Q000188:drug therapy*; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy*; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin